TY - JOUR
T1 - Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors
AU - Nieborowska-Skorska, Margaret
AU - Kopinski, Piotr K.
AU - Ray, Regina
AU - Hoser, Grazyna
AU - Ngaba, Danielle
AU - Flis, Sylwia
AU - Cramer, Kimberly
AU - Reddy, Mamatha M.
AU - Koptyra, Mateusz
AU - Penserga, Tyrone
AU - Glodkowska-Mrowka, Eliza
AU - Bolton, Elisabeth
AU - Holyoake, Tessa L.
AU - Eaves, Connie J.
AU - Cerny-Reiterer, Sabine
AU - Valent, Peter
AU - Hochhaus, Andreas
AU - Hughes, Timothy P.
AU - Van Der Kuip, Heiko
AU - Sattler, Martin
AU - Wiktor-Jedrzejczak, Wieslaw
AU - Richardson, Christine
AU - Dorrance, Adrienne
AU - Stoklosa, Tomasz
AU - Williams, David A.
AU - Skorski, Tomasz
PY - 2012/5/3
Y1 - 2012/5/3
N2 - Chronic myeloid leukemia in chronic phase (CML-CP) is induced by BCR-ABL1 oncogenic tyrosine kinase. Tyrosine kinase inhibitors eliminate the bulk of CML-CP cells, but fail to eradicate leukemia stem cells (LSCs) and leukemia progenitor cells (LPCs) displaying innate and acquired resistance, respectively. These cells may accumulate genomic instability, leading to disease relapse and/or malignant progression to a fatal blast phase. In the present study, we show that Rac2 GTPase alters mitochondrial membrane potential and electron flow through the mitochondrial respiratory chain complex III (MRC-cIII), thereby generating high levels of reactive oxygen species (ROS) in CML-CP LSCs and primitive LPCs. MRC-cIII-generated ROS promote oxidative DNA damage to trigger genomic instability, resulting in an accumulation of chromosomal aberrations and tyrosine kinase inhibitor-resistant BCR-ABL1 mutants. JAK2(V617F) and FLT3(ITD)-positive polycythemia vera cells and acute myeloid leukemia cells also produce ROS via MRC-cIII. In the present study, inhibition of Rac2 by genetic deletion or a small-molecule inhibitor and down-regulation of mitochondrial ROS by disruption of MRC-cIII, expression of mitochondriatargeted catalase, or addition of ROS-scavenging mitochondria-targeted peptide aptamer reduced genomic instability. We postulate that the Rac2-MRC-cIII pathway triggers ROS-mediated genomic instability in LSCs and primitive LPCs, which could be targeted to prevent the relapse and malignant progression of CML.
AB - Chronic myeloid leukemia in chronic phase (CML-CP) is induced by BCR-ABL1 oncogenic tyrosine kinase. Tyrosine kinase inhibitors eliminate the bulk of CML-CP cells, but fail to eradicate leukemia stem cells (LSCs) and leukemia progenitor cells (LPCs) displaying innate and acquired resistance, respectively. These cells may accumulate genomic instability, leading to disease relapse and/or malignant progression to a fatal blast phase. In the present study, we show that Rac2 GTPase alters mitochondrial membrane potential and electron flow through the mitochondrial respiratory chain complex III (MRC-cIII), thereby generating high levels of reactive oxygen species (ROS) in CML-CP LSCs and primitive LPCs. MRC-cIII-generated ROS promote oxidative DNA damage to trigger genomic instability, resulting in an accumulation of chromosomal aberrations and tyrosine kinase inhibitor-resistant BCR-ABL1 mutants. JAK2(V617F) and FLT3(ITD)-positive polycythemia vera cells and acute myeloid leukemia cells also produce ROS via MRC-cIII. In the present study, inhibition of Rac2 by genetic deletion or a small-molecule inhibitor and down-regulation of mitochondrial ROS by disruption of MRC-cIII, expression of mitochondriatargeted catalase, or addition of ROS-scavenging mitochondria-targeted peptide aptamer reduced genomic instability. We postulate that the Rac2-MRC-cIII pathway triggers ROS-mediated genomic instability in LSCs and primitive LPCs, which could be targeted to prevent the relapse and malignant progression of CML.
UR - http://www.scopus.com/inward/record.url?scp=84860819704&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000305284600022&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1182/blood-2011-10-385658
DO - 10.1182/blood-2011-10-385658
M3 - Article
C2 - 22411871
SN - 0006-4971
VL - 119
SP - 4253
EP - 4263
JO - Blood
JF - Blood
IS - 18
ER -